NASDAQ:ANEB Anebulo Pharmaceuticals (ANEB) Stock Price, News & Analysis $0.32 0.00 (0.00%) As of 12:18 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsSEC Filings About Anebulo Pharmaceuticals Stock (NASDAQ:ANEB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ANEB alerts:Sign Up Key Stats Today's Range$0.30▼$0.3350-Day Range$0.30▼$0.4252-Week Range$0.00▼$2.85Volume374 shsAverage Volume28,896 shsMarket Capitalization$13.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) is a clinical-stage biopharmaceutical company focused on developing treatments for acute cannabinoid intoxication and other conditions associated with cannabinoid use. The company’s work is aimed at addressing medical needs for patients experiencing severe or potentially dangerous effects from cannabis and related substances. Anebulo’s lead product candidate, ANEB-001, is an orally administered small-molecule antagonist of the cannabinoid 1 (CB1) receptor. The company is developing ANEB-001 as a potential treatment to rapidly reverse the effects of cannabinoid intoxication, with possible applications in acute cannabinoid poisoning and cannabinoid hyperemesis syndrome. Based in Austin, Texas, Anebulo conducts its operations through drug development and clinical research activities. The company’s programs are directed primarily toward the U.S. healthcare market, although successful development and regulatory approval could support broader use internationally. Anebulo is led by Chief Executive Officer Simon Allen.AI Generated. May Contain Errors. Read More Anebulo Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks1st Percentile Overall ScoreANEB MarketRank™: Anebulo Pharmaceuticals scored higher than 1% of companies evaluated by MarketBeat, and ranked 905th out of 908 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingAnebulo Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAnebulo Pharmaceuticals has received no research coverage in the past 90 days.Read more about Anebulo Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Anebulo Pharmaceuticals is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anebulo Pharmaceuticals is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnebulo Pharmaceuticals has a P/B Ratio of 1.16. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Anebulo Pharmaceuticals' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ANEB. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnebulo Pharmaceuticals does not currently pay a dividend.Dividend GrowthAnebulo Pharmaceuticals does not have a long track record of dividend growth. News and Social Media0.6 / 5News SentimentN/A Search Interest1 people have searched for ANEB on MarketBeat in the last 30 days. Company Ownership1.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Anebulo Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders80.60% of the stock of Anebulo Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions28.40% of the stock of Anebulo Pharmaceuticals is held by institutions.Read more about Anebulo Pharmaceuticals' insider trading history. Receive ANEB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anebulo Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ANEB Stock News HeadlinesAnebulo Pharmaceuticals (ANEB) to Post Earnings on WednesdaySeptember 16, 2026 | americanbankingnews.comANEBULO PHARMAC INC by Anebulo Pharmaceuticals Inc (ANEB) Stock Price, Quote, News & HistoryJuly 1, 2026 | benzinga.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 25 at 1:00 AM | Porter & Company (Ad)Anebulo’s Selonabant Phase 1 Completion: What Investors Should Watch NextMay 8, 2026 | tipranks.comAnebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent UpdatesFebruary 13, 2026 | finance.yahoo.comAnebulo Pharmaceuticals stock plunges after announcing Nasdaq delisting plansFebruary 6, 2026 | in.investing.comAnebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SECFebruary 6, 2026 | finance.yahoo.comAnebulo Pharmaceuticals Announces Final Results of Tender OfferJanuary 29, 2026 | finance.yahoo.comSee More Headlines ANEB Stock Analysis - Frequently Asked Questions How have ANEB shares performed this year? Anebulo Pharmaceuticals' stock was trading at $1.01 at the beginning of 2026. Since then, ANEB shares have decreased by 67.8% and is now trading at $0.3250. How were Anebulo Pharmaceuticals' earnings last quarter? Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) issued its quarterly earnings results on Monday, September, 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.05). When did Anebulo Pharmaceuticals IPO? Anebulo Pharmaceuticals (ANEB) raised $21 million in an initial public offering on Friday, May 7th 2021. The company issued 3,000,000 shares at $6.00-$8.00 per share. The Benchmark Company served as the underwriter for the IPO. How do I buy shares of Anebulo Pharmaceuticals? Shares of ANEB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Anebulo Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Anebulo Pharmaceuticals investors own include Hecla Mining (HL), Li Auto (LI), Norwegian Cruise Line (NCLH), PAR Technology (PAR), Transdigm Group (TDG) and Trade Desk (TTD). Company Calendar Last Earnings9/29/2025Today9/25/2026Next Earnings (Estimated)9/25/2026Fiscal Year End6/30/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (9m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 ANEB's financial health is in the Red zone, according to TradeSmith. ANEB has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ANEB CIK1815974 Webwww.anebulo.com Phone512-598-0931FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.48 million Net MarginsN/A Pretax MarginN/A Return on Equity-74.57% Return on Assets-68.96% Debt Debt-to-Equity RatioN/A Current Ratio6.24 Quick Ratio6.24 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.28 per share Price / Book1.16Miscellaneous Outstanding Shares40,785,000Free Float7,912,000Market Cap$13.26 million OptionableNot Optionable Beta-1.82 The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:ANEB) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anebulo Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Anebulo Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
